Comparison of 14-day bismuth-containing quadruple therapy for helicobacter pylori eradication with different antibiotic combinations in Liaoning area: A prospective study / 中国实用内科杂志

ABSTRACT

OBJECTIVE: To compare the eradication rate, adverse reactions and compliance of the two 14-day bismuth-containing quadruple therapies in Liaoning Province as the first-line Helicobacter pylori(HP) eradication programs. METHODS: We collected222 eligible HP-infected patients who were admitted to the First Affiliated Hospital of China Medical University from March 2017 to October 2018 and treated with either of the following two programs(1) EBLA group esomeprazole(20 mg, twice a day), bismuth(200 mg, twice a day), levofloxacin(200 mg, twice a day) and amoxicillin(1 g, twice a day), 111 cases in total;(2) EBCA groupesomeprazole(20 mg, twice a day), bismuth(200 mg, twice a day), clarithromycin(500 mg, twice a day) and amoxicillin(1 g, twice a day), 111 cases in total. The patients in both groups were given medicines for 14 days, and the 13 C breath test was performed after4 weeks of withdrawal. RESULTS: The eradication rate of EBLA group was 87.34%(95%CI 80.9%-93.9%), and that of EBCA group was 83.33%(95%CI 76%-90.7%).There was no significant difference between the two groups(P=0.413). The incidence of adverse reactions was 10.8% in EBLA group and 26.13% in EBCA group. The difference was statistically significant(P=0.003). The compliance of patients in EBLA group was 99.10%, and that of EBCA group was 98.20%. The difference was not statistically significant(P=0.561).CONCLUSION: Both EBLA program and EBCA program can achieve good eradication rate and compliance in Liaoning province. The incidence of adverse reactions in EBLA group is lower than that in EBCA group, which is the preferred first-line HP eradication program.